Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

King Pharmaceuticals Extends Alpharma Buyout Offer

By Pharmaceutical Processing | December 22, 2008

NEW YORK (AP) — King Pharmaceuticals Inc. extended its $37-per-share buyout offer for Alpharma Inc. on Monday and has already acquired about 92 percent of the company’s outstanding stock. The offer is now extended to 10.a.m. Dec. 29. It was set to expire Dec. 19.Bridgewater, N.J.-Alpharma agreed to Bristol, Tenn.-based King’s $1.6 billion cash takeover offer in November, ending the drugmakers’ months-long battle. The offer represented a 54 percent premium to Alpharma shareholders. Alpharma previously rejected a $1.4 billion offer from King, which then raised its bid and said it would take the offer directly to shareholders. Both boards of directors have since unanimously approved the deal. As of Dec. 19, King had bought just over 38.6 million shares of Alpharma’s stock, representing 92.2 percent of shares outstanding. A key goal of the deal is to expand King’s pain drug franchise, which consists of the chronic pain treatment Avinza and the muscle relaxant Skelaxin. They made up about half of the company’s revenue in 2007. Alpharma gets most of its revenue from animal health products, though the bulk of its pharmaceutical sales come from the morphine painkiller Kadian. It also launched the Flector Patch, a pain treatment, in January. King, meanwhile, is developing the abuse-resistant pain drug Remoxy with partner Pain Therapeutics Inc. while Alpharma has a tamper-resistant morphine pill called Embeda under review. Credit Suisse and Wachovia Securities are acting as financial advisers, and Dewey & LeBoeuf LLP is acting as legal counsel to King.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE